Related Experiment Video

Updated: Aug 19, 2026

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Overview of monoclonal antibodies in cancer therapy: present and promise

M Stern1, R Herrmann

  • 1Department of Hematology, University Hospital Basel, Switzerland.

Critical Reviews in Oncology/Hematology
|March 23, 2005
PubMed

Insights

Monoclonal antibody therapy, particularly in oncology, has seen significant advancements. This review covers three decades of development, clinical outcomes, and future prospects for these targeted cancer treatments.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Monoclonal antibody therapy has evolved over 30 years.
  • Clinical applications are most prevalent in oncology, with numerous agents in development.
  • Recent FDA approvals include radiolabeled and growth factor receptor-targeting antibodies.

Purpose of the Study:

  • To review the development of monoclonal antibody therapy over three decades.
  • To examine treatment outcomes of newly approved and established monoclonal antibodies.
  • To provide an outlook on future directions in antibody-based therapies.

Main Methods:

  • Literature review of monoclonal antibody development and clinical trials.
  • Analysis of treatment outcomes for approved monoclonal antibodies in oncology.
  • Synthesis of data on standard and experimental applications of antibody therapies.

Main Results:

  • Significant progress in monoclonal antibody therapy, especially in oncology.
  • Recent approvals of novel agents like (131)I-tositumomab, bevacizumab, and cetuximab.
  • Established antibodies such as rituximab, trastuzumab, and alemtuzumab are widely used.

Conclusions:

  • Monoclonal antibody therapy is a rapidly advancing and promising treatment modality.
  • Continued research and development are expected to yield further innovations.
  • These targeted therapies are transforming cancer treatment paradigms.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...